The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults
Open accessAbstract
Summary: VRC-HIVMAB060-00-AB (VRC01) is a broadly neutralizing HIV-1 monoclonal antibody (mAb) isolated from the B cells of an HIV-infected patient. It is directed against the HIV-1 CD4 binding site and is capable of potently neutralizing the majority of diverse HIV-1 strains. This Phase I dose-escalation study in healthy adults was conducted at the National Institutes of Health (NIH) Clinical Center (Bethesda, MD, USA). Primary objectives were the safety, tolerability and pharmacokinetics (PK) of VRC01 intravenous (i.v.) infusion at 5, 20 or 40 mg/kg, given either once (20 mg/kg) or twice 28 days apart (all doses), and of subcutaneous (s.c.) delivery at 5 mg/kg compared to s.c. placebo given twice, 28 days apart. Cumulatively, 28 subjects received 43 VRC01 and nine received placebo administrations. There were no serious adverse events or dose-limiting toxicities. Mean 28-day serum trough concentrations after the first infusion were 35 and 57 μg/ml for groups infused with 20 mg/kg (n = 8) and 40 mg/kg (n = 5) doses, respectively. Mean 28-day trough concentrations after the second infusion were 56 and 89 μg/ml for the same two doses. Over the 5–40 mg/kg i.v. dose range (n = 18), the clearance was 0·016 l/h and terminal half-life was 15 days. After infusion VRC01 retained expected neutralizing activity in serum, and anti-VRC01 antibody responses were not detected. The human monoclonal antibody (mAb) VRC01 was well tolerated when delivered i.v. or s.c. The mAb demonstrated expected half-life and pharmacokinetics for a human immunoglobulin G. The safety and PK results support and inform VRC01 dosing schedules for planning HIV-1 prevention efficacy studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01
Li, Y., O'Dell, S., Walker, L. M., Wu, X., Guenaga, J., Feng, Y., Schmidt, S. D., McKee, K., Louder, M. K., Ledgerwood, J. E., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00754-11 · Cited by 235
Self-citation
Cited by
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Corey, L., Gilbert, P. B., Juraska, M., Montefiori, D. C., Morris, L., Karuna, S. T., Edupuganti, S., Mgodi, N. M., deCamp, A. C., Rudnicki, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031738 · Cited by 538
Self-citationAntibody 10-1074 suppresses viremia in HIV-1-infected individuals
Caskey, M., Schoofs, T., Gruell, H., Settler, A., Karagounis, T., Kreider, E. F., Murrell, B., Pfeifer, N., Nogueira, L., Oliveira, T. Y., et al. (2017) · Nature Medicine · doi:10.1038/nm.4268 · Cited by 487
Lynch, R. M., Boritz, E., Coates, E. E., DeZure, A., Madden, P., Costner, P., Enama, M. E., Plummer, S., Holman, L., Hendel, C. S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5752 · Cited by 465
Self-citationEffect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
Bar, K. J., Sneller, M. C., Harrison, L. J., Justement, J. S., Overton, E. T., Petrone, M. E., Salantes, D. B., Seamon, C. A., Scheinfeld, B., Kwan, R. W., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1608243 · Cited by 455
Self-citationPardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352
Metadata
- Authors
- VRC 602 Study Team, Ledgerwood, J. E., Coates, E. E., Yamshchikov, G., Saunders, J. G., Holman, L., Enama, M. E., DeZure, A., Lynch, R. M., Gordon, I., Plummer, S., Hendel, C. S., Pegu, A., Conan-Cibotti, M., Sitar, S., Bailer, R. T., Narpala, S., McDermott, A., Louder, M., O'Dell, S., Mohan, S., Pandey, J. P., Schwartz, R. M., Hu, Z., Koup, R. A., Capparelli, E., Mascola, J. R., & Graham, B. S.
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-09-24
- Volume
- 182
- Issue
- 3
- Pages
- 289-301
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- OpenAlex
- W1924338894
- Cited by
- 247
- References
- 1
- FWCI
- 15.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. https://app.cochat.ai/papers/10.1111/cei.12692
- The paper
- VRC 602 Study Team, Ledgerwood, J. E., Coates, E. E., Yamshchikov, G., Saunders, J. G., Holman, L., Enama, M. E., DeZure, A., Lynch, R. M., Gordon, I., Plummer, S., Hendel, C. S., Pegu, A., Conan-Cibotti, M., Sitar, S., Bailer, R. T., Narpala, S., McDermott, A., Louder, M., . . . Graham, B. S. (2015). Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clinical and Experimental Immunology. https://doi.org/10.1111/cei.12692
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.